Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEX regimen in advanced gastric cancer
NCT00511446Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Aug 2007
- Primary completion
- May 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, oxaliplatin, capecitabine in gastric cancer (GC), sponsored by Martin Luther University Halle-Wittenberg. Started Aug 2007; status: completed.
02
Drugs
docetaxeloxaliplatincapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00511446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511446.